Antiangiogenic Biotherapy and Chemotherapy in Breast Cancer: Review of Literature and Case Report
Authors:
M. Sochor 1; P. Chlebus 2
Authors place of work:
Centrum pro klinickou a radiační onkologii, Krajská nemocnice Liberec, a. s., Liberec
1; Radiodiagnostické oddělení, Krajská nemocnice Liberec, a. s., Liberec
2
Published in the journal:
Klin Onkol 2013; 26(2): 91-98
Category:
Case Report
Summary
Breast cancer incidence is 120/100,000 women and thus, it is the most frequent malignant disease in women. Despite the ever-increasing incidence, mortality has stayed stable; this is due to screening with detection of early breast cancers, adjuvant treatment and advances in targeted therapy. Currently, we perceive breast cancer as a phenotypically different subunits, influenced by genetic and epigenetic changes. All 5 basic subgroups (luminal A, B, basal-like, HER-2 positive and claudin-low) vary significantly in their prognosis and therapeutic options. The subgroup of basal-like tumors without hormone receptors positivity and HER-2 antigen (triple-negative breast cancer) is prognostically and therapeutically a very unfavorable group. Hormonal and anti-HER-2 therapy is excluded, and the effect of chemotherapy is limited and short-lived. Research for this sub-group of breast tumors in recent years focused on the influence of angiogenesis and DNA repair systems. Therapeutic manipulation of angiogenesis is based on the concept of its influence in the development and maintenance of the malignant process. The longest used and in terms of studies and clinical practice explored treatment is the main path of angiogenesis, the vascular endothelial growth factor. In the last few years, the real effect in the metastatic breast cancer is discussed. The initial positive results of pilot clinical trials showing a significant extension of the progression free survival bring disappointment since they were not translated into prolongation of overall survival. The following case-report presents a patient with metastatic triple-negative breast cancer with combined chemobiotherapy (capecitabine + bevacizumab). In the second part of the article, we discuss possible causes of inconsistent outcomes with antiangiogenic therapy in breast cancer, new directions in scientific research and today knowledge of prediction of its therapeutic effect.
Key words:
angiogenesis – metastatic breast cancer – bevacizumab – antiangiogenic therapy – prognostic factors
Zdroje
1. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357(26): 2666–2676.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57–70.
3. Gasparini G, Toi M, Gion M et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997; 89(2): 139–147.
4. Linderholm B, Grankvist K, Wilking N et al. Correlation of vascular endothelial growth factor content with recurrences, survival and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 2000; 18(7): 1423–1431.
5. Foekens JA, Peters HA, Grebenchtchikov N et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001; 61(14): 5407–5414.
6. Relf M, LeJeune S, Scott PA et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57(5): 963–969.
7. Konecny EG, Meng YG, Untch M et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004;10(5): 1706–1716.
8. Linderholm BK, Hellborg H, Johansson U et al. Significiantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 2009; 20(10): 1639–1646.
9. Boneberg EM, Legler DF, Hoefer MM et al. Angiogenesis and lymphangiogenesis are downregulated in primary breast cancer. Br J Cancer 2009; 101(4): 605–614.
10. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8(8): 592–603.
11. Mueller MD, Vigne JL, Minchenko A et al. Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alfa and beta. Proc Natl Acad Sci USA 2000; 97(20): 10972–10977.
12. Klos KS, Wyszomierski SL, Sun M et al. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res 2006; 66(4): 2028–2037.
13. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669–676.
14. Moore A. Breast-cancer therapy – looking back to the future. N Engl J Med 2007; 357(15): 1547–1549.
15. Brown LF, Berse B, Jackman RW et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptor in breast cancer. Hum Pathol 1995; 26(1): 86–91.
16. Pavlakis K, Messini I, Vrekoussis T et al. The assessment of angiogenesis and fibroblastic stromagenesis in hyperplastic and pre-invasive breast lesions. BMC Cancer 2008; 8: 88.
17. Eyler CE, Rich JN. Survival of the Fittest: Cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008; 26(17): 2839–2845.
18. Kaufmann M, von Minckwitz G, Smith R et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003; 21(13): 2600–2608.
19. Derleth C, Mayer IA. Antiangiogenic therapies in early-stage breast cancer. Clin Breast Cancer 2010; 10 (Suppl 1): E23–E31.
20. Bear HD, Tang G, Rastogi P et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012; 366(4): 310–320.
21. von Minckwitz G, Eidtmann H, Rezai M et al. German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366(4): 299–309.
22. Untch M, Fasching PA, Konecny GE et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results of the TECHNO trial of the AGO and CGC study groups. J Clin Oncol 2011; 29(25): 3351–3357.
23. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26(8): 1275–1281.
24. Mayer EL, Miller K, Rugo H et al. A pilot study of adjuvantn bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer. J Clin Oncol 2008; 26 (Suppl 15): s11, Abstract 519.
25. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99(16): 1232–1239.
26. Nalluri SR, Chu D, Keresztes R et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300(19): 2277–2285.
27. O‘Shaughnessy J, Miles D, Gray RJ et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 2010; 28 (Suppl): 15s, Abstract 1005.
28. Miller KD, Chap LI, Holmes FA et al. Randomized pha-se III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23(4): 792–799.
29. Muta M, Yanagawa T, Sai Y et al. Effect of low-dose paclitaxel and docetaxel on endothelial progenitor cells. Oncology 2009; 77(3–4): 182–191.
30. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011; 305(58): 487–494.
31. Ebos JM, Lee CR, Cruz-Munoz W et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15(3): 232–239.
32. Páez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15(3): 220–231.
33. Mancuso MR, Davis R, Norberg SM et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006; 116(10): 2610–2621.
34. Ebos JM, Kerbel RS. Antiangiogenic therapy: Impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011; 8(4): 210–221.
35. Miles D, Harbeck N, Escudier B et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2011; 29: 83–88.
36. Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: New rationale for new directions. Nat Rev Clin Oncol 2010; 7(8): 455–465.
37. Kerbel RS, Kamen BA. The anti-angiogenc basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4(6): 423–436.
38. Dellapasqua S, Bertolini F, Bagnardi V et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008; 26(30): 4899–4905.
39. Bagri A, Berry L, Gunter B et al. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin Cancer Res 2010; 16(15): 3887–3900.
40. Von Minckwitz G, Rezai M, Fasching PA et al. Neoadjuvant chemotherapy with or without bevacizumab: primary efficacy endpoint analysis of the GEPARQUINTO study (CBG 44). Cancer Res 2010; 70 (Suppl): 86, Abstract 235.
41. Munoz R, Man S, Shaked Y et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 2006; 66(7): 3386–3391.
42. Rosen LS, Ashurts HL, Chap L. Targeting signal transduction pathways in metastatic breast cancer: A comprehensive review. Oncologist 2010; 16(3): 216–235.
43. Schneider BP, Sledge GW Jr. Anti-VEGF therapy as adjuvant therapy: Clouds on the horizon? Breast Cancer Res 2009; 11(3): 303.
44. Ocaña A, Amir E, Vera F et al. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol 2011; 29(3): 254–256.
45. Casanovas O, Hicklin DJ, Bergers D et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8(4): 299–309.
46. Jain RK, Duda DG, Willet CG et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009; 6(6): 327–338.
47. Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010; 11(12): 1172–1183.
48. Chun YS, Vauthey JN, Boonsirikamchai P et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009; 302(21): 2338–2344.
49. Miller JC, Pien HH, Sahani D et al. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 2005; 97(3): 172–187.
50. O‘Connor JP, Jackson A, Asselin MC et al. Quantitative imaging biomarkers in the clinical development of targeted therapeutics current and future perspectives. Lancet Oncol 2008; 9(8): 766–776.
51. Nagengast WB, deVries EG, Hospers GA et al. In vivo VEGF imaging with radiolabeled bevacizumab in human ovarian tumor xenograft. J Nucl Med 2007; 48(8): 1313–1319.
52. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19(4): 1207–1225.
53. Bernaards C, Hedge P, Chen D et al. Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancer: analysis of pha-se III studies. J Clin Oncol 2010; 28 (Suppl): 15s, Abstract 10519.
54. Rüegg C, Meuwly JY, Driscol R et al. The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials. Curr Mol Med 2003; 3(8): 673–691.
55. Dowlati A, Gray R, Sandler AB et al. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab: an Eastern Cooperative Oncology Study Group. Clin Cancer Res 2008; 14(5): 1407–1412.
56. Duda DG, Cohen KS, Ancukiewicz M et al. A comparative study of circulating endothelial cells (CECs) and circulating progenitor cells (CPCs) kinetics in four multidisciplinary phase II studies of antiangiogenic agents. J Clin Oncol 2008; 26 (Suppl): 15s, Abstract 3544.
57. Baar J, Silverman P, Lyons J et al. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin Cancer Res 2009; 15(10): 3583–3590.
58. Gao D, Nolan D, McDonnell K et al. Bone marrow-derived endothelial progenitor cells contribute to angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta 2009; 1796(1): 33–40.
59. Schneider BP, Wang M, Radovich M et al. ECOG 2100. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in trial of paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008; 26(28): 4672–4678.
60. Schultheis AM, Lurje G, Rhodes KE et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 2008; 14(22): 7554–7563.
61. Hlatky L, Hahnfeldt P, Folkma J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn‘t tell us. J Natl Cancer Inst 2002; 94(12): 883–893.
62. Hurwitz H, Douglas PS, Middleton JP et al. Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). J Clin Oncol 2010; 28 (Suppl): 15s, abstr 3039.
63. Smith I. Goals of treatment for patients with metastatic breast cancer. Semin Oncol 2006; 33 (1 Suppl 2): S2–S5.
64. Sherrill B, Amonkar M, Wu Y et al. Relationship between effects of time-to-disease progression and overall survival in studies of metastatic breast cancer. Br J Cancer 2008; 99(10): 1572–1578.
65. Verma S, McLeod D, Batist G et al. In the end what matters most? A review of clinical endpoints in advanced breast cancer. The Oncologist 2011; 16(1): 25–35.
66. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression free survival. J Natl Cancer Inst 2009; 101(23): 1642–1649.
67. Alvarez RH, Guarneri V, Icli F et al. Bevacizumab treatment for advanced breast cancer. Oncologist 2011; 16(12): 1684–1697.
29. Miles DW, de Haas SL, Dirix L et al. Plasma biomarker analyses in the AVADO phase III randomized study of first-line bevacizumab plus docetaxel in patients with HER2-negative metastatic breast cancer. Cancer Res 2010; 70 (Suppl): 235s, Abstract P2-16-04.
Štítky
Paediatric clinical oncology Surgery Clinical oncologyČlánok vyšiel v časopise
Clinical Oncology
2013 Číslo 2
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
- Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
Najčítanejšie v tomto čísle
- Prognostic Factors for Cervical Cancer
- Spontaneous Remission of Acute Myeloid Leukemia – a Single Center Case Reports
- A Case Report: Neutropenia Grade IV and Febrile Neutropenia in a Metastatic Breast Cancer Patient Treated With Palliative Chemotherapy Cyclophosphamide/Myocet
- The Role of Radiotherapy in the Treatment of Malignant Lymphomas – Recommendations of the Czech Lymphoma Study Group